CO2019001111A2 - Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos - Google Patents

Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos

Info

Publication number
CO2019001111A2
CO2019001111A2 CONC2019/0001111A CO2019001111A CO2019001111A2 CO 2019001111 A2 CO2019001111 A2 CO 2019001111A2 CO 2019001111 A CO2019001111 A CO 2019001111A CO 2019001111 A2 CO2019001111 A2 CO 2019001111A2
Authority
CO
Colombia
Prior art keywords
antibodies
zika virus
specifically bind
new antibodies
relates
Prior art date
Application number
CONC2019/0001111A
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of CO2019001111A2 publication Critical patent/CO2019001111A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • G01N2333/183Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a anticuerpos, y fragmentos de unión a antígeno de los mismos, que neutralizan potentemente la infección por el virus del Zika (ZIKV). La invención también se refiere a los sitios antigénicos a los que se unen los anticuerpos y fragmentos de unión a antígeno, así como a los ácidos nucleicos que codifican e inmortalizan las células B que producen dichos anticuerpos y fragmentos de anticuerpos. Además, la invención se refiere al uso de los anticuerpos y fragmentos de anticuerpos de la invención en métodos de análisis, así como en el diagnóstico, profilaxis y tratamiento de la infección por ZIKV.
CONC2019/0001111A 2016-07-13 2019-02-05 Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos CO2019001111A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/066684 WO2018010789A1 (en) 2016-07-13 2016-07-13 Novel antibodies specifically binding to zika virus epitopes and uses thereof
PCT/EP2017/067581 WO2018011283A1 (en) 2016-07-13 2017-07-12 Novel antibodies specifically binding to zika virus epitopes and uses thereof

Publications (1)

Publication Number Publication Date
CO2019001111A2 true CO2019001111A2 (es) 2019-08-20

Family

ID=56413654

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0001111A CO2019001111A2 (es) 2016-07-13 2019-02-05 Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos

Country Status (30)

Country Link
US (3) US11117954B2 (es)
EP (2) EP4342911A1 (es)
JP (2) JP7252888B2 (es)
KR (1) KR102595764B1 (es)
CN (2) CN109563157B (es)
BR (1) BR112018074456A2 (es)
CA (1) CA3024374A1 (es)
CL (2) CL2019000067A1 (es)
CO (1) CO2019001111A2 (es)
CR (1) CR20190066A (es)
DK (1) DK3484915T3 (es)
DO (2) DOP2019000006A (es)
EA (1) EA201990243A1 (es)
EC (1) ECSP19009170A (es)
ES (1) ES2959883T3 (es)
FI (1) FI3484915T3 (es)
HR (1) HRP20231196T1 (es)
HU (1) HUE063272T2 (es)
IL (1) IL262710B2 (es)
LT (1) LT3484915T (es)
MX (1) MX2019000526A (es)
MY (1) MY190553A (es)
PE (1) PE20190398A1 (es)
PH (1) PH12018502348A1 (es)
PL (1) PL3484915T3 (es)
SG (1) SG11201809879WA (es)
SI (1) SI3484915T1 (es)
UA (1) UA126381C2 (es)
WO (2) WO2018010789A1 (es)
ZA (1) ZA201807467B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6998935B2 (ja) 2016-07-13 2022-01-18 エボニック オペレーションズ ゲーエムベーハー 溶解された脂質含有バイオマスから脂質を分離する方法
CU20190036A7 (es) 2016-10-13 2019-11-04 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP3527664A1 (en) 2018-02-15 2019-08-21 Evonik Degussa GmbH Method of isolating lipids from a lipids containing biomass
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
US11884718B2 (en) 2018-04-24 2024-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
US11976253B2 (en) 2018-05-15 2024-05-07 Evonik Operations Gmbh Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion
CA3101855C (en) 2018-05-15 2023-06-20 Evonik Operations Gmbh Method of isolating lipids from a lipids containing biomass with aid of hydrophobic silica
WO2020061159A1 (en) * 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
BR112021008217A2 (pt) * 2018-10-31 2021-08-17 Icahn School Of Medicine At Mount Sinai anticorpos humanos que têm como alvo vírus zika ns1, polipeptídeos ns1 e seus usos
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン,インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
WO2020245663A1 (en) * 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
BR112022009574A2 (pt) * 2019-11-19 2022-08-02 Univ Vanderbilt Anticorpos humanos que neutralizam o vírus zika e métodos de uso dos mesmos
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
JP7471555B2 (ja) 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
US20230324404A1 (en) 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
CN115697392A (zh) * 2020-06-28 2023-02-03 神州细胞工程有限公司 一种降低病毒ade效应的方法
WO2022212858A2 (en) * 2021-04-01 2022-10-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
CN112921124B (zh) * 2021-04-08 2021-09-28 广东创晟控股集团有限公司 一种快速检测病毒的试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
EP3689902B1 (en) * 2013-03-15 2023-06-28 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
JP2019511221A (ja) 2016-03-11 2019-04-25 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 弱毒化された生ジカウイルスワクチン
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
CN117946114A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途

Also Published As

Publication number Publication date
KR20190027382A (ko) 2019-03-14
JP2023062036A (ja) 2023-05-02
DK3484915T3 (da) 2023-10-09
JP7252888B2 (ja) 2023-04-05
US11912757B2 (en) 2024-02-27
MY190553A (en) 2022-04-27
US20210363227A1 (en) 2021-11-25
AU2017297757A1 (en) 2018-11-22
WO2018011283A1 (en) 2018-01-18
EP3484915A1 (en) 2019-05-22
PE20190398A1 (es) 2019-03-13
SG11201809879WA (en) 2018-12-28
IL262710B2 (en) 2024-05-01
CL2021002994A1 (es) 2022-09-09
HUE063272T2 (hu) 2024-01-28
DOP2019000006A (es) 2019-03-31
ES2959883T3 (es) 2024-02-28
FI3484915T3 (fi) 2023-11-15
SI3484915T1 (sl) 2024-02-29
IL262710A (en) 2018-12-31
US20210355198A1 (en) 2021-11-18
CA3024374A1 (en) 2018-01-18
HRP20231196T1 (hr) 2024-01-19
IL262710B1 (en) 2024-01-01
MX2019000526A (es) 2019-05-02
LT3484915T (lt) 2023-10-10
JP2019533425A (ja) 2019-11-21
EA201990243A1 (ru) 2019-07-31
CN116199775A (zh) 2023-06-02
CN109563157A (zh) 2019-04-02
BR112018074456A2 (pt) 2019-03-19
ZA201807467B (en) 2024-04-24
CL2019000067A1 (es) 2019-07-26
US11117954B2 (en) 2021-09-14
DOP2021000026A (es) 2021-07-30
WO2018010789A1 (en) 2018-01-18
CR20190066A (es) 2019-09-10
UA126381C2 (uk) 2022-09-28
ECSP19009170A (es) 2019-02-28
PL3484915T3 (pl) 2024-03-25
US20190256582A1 (en) 2019-08-22
EP4342911A1 (en) 2024-03-27
PH12018502348A1 (en) 2019-03-25
CN109563157B (zh) 2023-01-17
KR102595764B1 (ko) 2023-10-30
EP3484915B1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
CO2019001111A2 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
EA202191751A1 (ru) Гуманизированное антитело против pd-1 человека
NI201700018A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
EA201890874A1 (ru) Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
PE20170766A1 (es) Moleculas de union tri-especificas que se unen especificamente a varios antigenos de cancer y metodos de uso de los mismos
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201791270A1 (ru) Модифицированные april-связывающие антитела
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora